Mukka Proteins reappoints board, KMPs for five-year terms
Mukka Proteins Ltd reappointed three independent directors and three key managerial personnel for five-year terms starting in January 2027. The board approved the moves on August 12, 2026, following Nomination and Remuneration Committee recommendations. Shareholder approval at the 16th AGM is required.

*this image is generated using AI for illustrative purposes only.
Mukka Proteins board of directors approved the reappointment of three independent directors and three key managerial personnel for five-year terms during a meeting held on August 12, 2026. The appointments, which commence in January 2027, are subject to shareholder approval at the company’s 16th Annual General Meeting.
The board acted on recommendations from the Nomination and Remuneration Committee to secure leadership continuity across both oversight and executive functions. The reappointments cover the period from mid-January 2027 to mid-January 2032 for independent directors, and from late January 2027 to late January 2032 for key managerial personnel.
Independent Director Reappointments
Three non-executive independent directors were approved for their second consecutive five-year terms:
- Mr. Karkala Shankar Balachandra Rao (DIN: 03589394)
- Mr. Hamad Bava (DIN: 094423)
- Mr. Narendra Surendra Kamath (DIN: 07255904)
These directors are not liable to retire by rotation. Their terms begin on January 15, 2027, and end on January 14, 2032.
Key Managerial Personnel Reappointments
Three whole-time directors and executives were also approved for five-year terms beginning January 20, 2027:
| Name | Role | Retire by Rotation |
|---|---|---|
| Kalandan Mohammed Haris | Managing Director and CEO | No |
| Kalandan Mohammed Althaf | Whole-Time Director and CFO | Yes |
| Kalandan Mohammad Arif | Whole-Time Director and COO | Yes |
Mr. Haris, who serves as managing director and chief executive officer, is not liable to retire by rotation. Mr. Althaf, the chief financial officer, and Mr. Arif, the chief operating officer, are liable to retire by rotation.
Governance Compliance
The disclosures comply with Regulation 30(6) read with Schedule III of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The board confirmed that none of the appointees are debarred from holding office by virtue of any SEBI order or other authority.
The meeting commenced at 3:30 pm and concluded at 4:15 pm. Mehaboobsab Mahmadgous Chalyal, company secretary and compliance officer, certified the disclosure.
Historical Stock Returns for Mukka Proteins
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.68% | +5.36% | +0.75% | -1.63% | -10.48% | -42.77% |
How might Mukka Proteins' strategy of securing five-year leadership terms influence investor confidence regarding corporate stability and long-term strategic execution?
What specific operational or financial targets has the reappointed CEO and CFO outlined for the 2027-2032 period to justify this extended leadership continuity?
Given that two of the three key managerial personnel are liable to retire by rotation, what succession plans or contingency measures are in place to mitigate potential governance disruptions?


































